老年人多重用药与抑郁症的关系研究进展

doi:10.3969/j.issn.1003-9198.2023.03.004

摘要/Abstract

中图分类号:

R 592

张飞, 李铭麟, 王逸飞, 王佳贺. 老年人多重用药与抑郁症的关系研究进展[J]. 实用老年医学, 2023, 37(3): 226-229.

[1] 李慧芳, 杨贵荣, 杨长春, 等. 老年综合征及老年综合评估应用进展[J]. 中国全科医学, 2020, 23(8): 993-998.
[2] WONGPAKARAN N, WONGPAKARAN T, SIRIRAK T, et al. Predictors of polypharmacy among elderly Thais with depressive and anxiety disorders: findings from the DAS study[J]. BMC Geriatr, 2018, 18(1):309.
[3] 李荔, 李莎, 卫芸, 等. 社区老年人多重用药率及其相关因素的系统综述[J]. 中国全科医学,2021, 24(25):3161-3170.
[4] ALJAWADI M H, KHOJA A T, ALABOUD N M, et al. Prevalence of polypharmacy and factors associated with it among saudi older adults - Results from the Saudi National Survey for Elderly Health (SNSEH)[J]. Saudi Pharm J, 2022, 30(3):230-236.
[5] DUMAN R S, AGHAJANIAN G K, SANACORA G, et al. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants[J]. Nat Med, 2016, 22(3):238-249.
[6] AGUSTINI B, LOTFALIANY M, WOODS R L, et al. Patterns of association between depressive symptoms and chronic medical morbidities in older adults[J]. Geriatrics, 2020, 68(8):1834-1841.
[7] WIERSEMA C, OUDE VOSHAAR R C, VAN DEN BRINK R H S, et al. Determinants and consequences of polypharmacy in patients with a depressive disorder in later life[J]. Acta Psychiatr Scand, 2022, 146(1):85-97.
[8] WOLFF J, REIßNER P, HEFNER G, et al. Pharmaco therapy, drug-drug interactions and potentially inappropriate medication in depressive disorders[J]. PLoS One, 2021, 16(7):e0255192.
[9] GHAED-SHARAF M, HARIRI S, POUSTCHI H, et al. The pattern of medication use, and determinants of the prevalence of polypharmacy among patients with a recent history of depressive disorder: results from the pars cohort study[J]. BMC Psychol, 2022, 10(1):12.
[10] HUANG Y T, STEPTOE A, WEI L, et al. Dose-response relationships between polypharmacy and all-cause and cause-specific mortality among older people[J]. J Gerontol A Biol Sci Med Sci, 2022, 77(5):1002-1008.
[11] ALMODÓVAR A S, NAHATA M C. Associations between chronic disease, polypharmacy, and medication-related problems among medicare beneficiaries[J]. J Manag Care Spec Pharm, 2019, 25(5):573-577.
[12] KISS A, MENUS A, TOTH K, et al. Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure[J]. Eur Arch Psychiatry Clin Neurosci, 2020, 270(1):71-82.
[13] EYIGOR S, KUTSAL Y G, TORAMAN F, et al. Polypharmacy, physical and nutritional status, and depression in the elderly: do polypharmacy deserve some credits in these problems?[J]. Exp Aging Res, 2021, 47(1):79-91.
[14] MÖLLER J, RAUSCH C, LAFLAMME L, et al. Geriatric syndromes and subsequent health-care utilization among older community dwellers in Stockholm[J]. Eur J Ageing, 2022, 19(1):19-25.
[15] CHENG C, BAI J. Association between polypharmacy, anxiety, and depression among chinese older adults: evidence from the Chinese Longitudinal Healthy Longevity Survey[J]. Clin Interv Aging, 2022, 17:235-244.
[16] BAZARGAN M, SMITH J, SAQIB M, et al. Associations between polypharmacy, self-rated health, and depression in African American older adults; mediators and moderators[J]. Int J Environ Res Public Health, 2019, 16(9):1574.
[17] ASSARI S, WISSEH C, SAQIB M, et al. Polypharmacy and depressive symptoms in U.S.-born Mexican American older adults[J]. Psych, 2019, 1(1):491-503.
[18] LIU C P, LEUNG D S, CHI I. Social functioning, polypharmacy and depression in older Chinese primary care patients[J]. Aging Ment Health, 2011, 15(6):732-741.
[19] IDIL E, AYDIN A E, ATES BULUT E, et al. Rationally decreasing the number of drugs seems to be a useful therapeutic approach in older adults: 6-month follow-up study[J]. Arch Gerontol Geriatr, 2021, 96:104472.
[20] HOLVAST F, VAN HATTEM B A, SINNIGE J, et al. Late-life depression and the association with multimorbidity and polypharmacy: a cross-sectional study[J]. Fam Pract, 2017, 34(5):539-545.
[21] CHOI N G, MARTI C N, KUNIK M E. Predictors of CNS-active medication use and polypharmacy among homebound older adults with depression[J]. Psychiatr Serv, 2020, 71(8):847-850.
[22] HUANG S S, CHEN H H, WANG J, et al. Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study[J]. BMC Psychiatry, 2020, 20(1):541.
[23] HIANCE-DELAHAYE A, DE SCHONGOR F M, LECHOWSKI L, et al. Potentially inappropriate prescription of antidepressants in old people: characteristics, associated factors, and impact on mortality[J]. Int Psychogeriatr, 2018, 30(5):715-726.
[24] STASSEN H H, BACHMANN S, BRIDLER R, et al. Inflammatory processes linked to major depression and schizophrenic disorders and the effects of polypharmacy in psychiatry: evidence from a longitudinal study of 279 patients under therapy[J]. Eur Arch Psychiatry Clin Neurosci, 2021, 271(3):507-520.
[25] ARNONE D, GALADARI H, RODGERS C J, et al. Efficacy of onabotulinumtoxinA in the treatment of unipolar major depression: systematic review, meta-analysis and meta-regression analyses of double-blind randomised controlled trials[J]. J Psychopharmacol, 2021, 35(8):910-918.
[26] MILLÁN-CALENTI J C, MARTíNEZ-ISASI S, LORENZO-LÓPEZ L, et al. Morbidity and medication consumption among users of home telecare services[J]. Health Soc Care Community, 2017, 25(3):888-900.
[27] WU C S, TSAI Y T, HSIUNG C A, et al. Comparative risk of ventricular arrhythmia and sudden cardiac death across antidepressants in patients with depressive disorders[J]. J Clin Psychopharmacol, 2017, 37(1):32-39.
[28] AILABOUNI N, MANGIN D, NISHTALA P S. DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities[J]. Int J Clin Pharm, 2019, 41(1):167-178.
[29] LAZRIS A. Geriatric palliative care[J]. BMC Primary Care, 2019, 46(3):447-459.
[30] BARONE P. Treatment of depressive symptoms in Parkinson’s disease[J]. Eur J Paediatr Neurol, 2011, 18 (Suppl 1):11-15.
[31] HOLVAST F, MASSOUDI B, OUDE VOSHAAR R C, et al. Non-pharmacological treatment for depressed older patients in primary care: a systematic review and meta-analysis[J]. PLoS One, 2017, 12(9):e0184666.
[32] TREVIZOL A P, GOLDBERGER K W, MULSANT B H, et al. Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant late-life depression[J]. Int J Geriatr Psychiatry, 2019, 34(6):822-827.
[33] ZANETIDOU S, BELVEDERI MURRI M, MENCHETTI M, et al. Physical exercise for late-life depression: customizing an intervention for primary care[J]. J Am Geriatr Soc, 2017, 65(2):348-355.

老年人多重用药与抑郁症的关系研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10

[1]	袁勇贵, 汪天宇. 前言——关注老年慢性病病人心身健康问题刻不容缓[J]. 实用老年医学, 2024, 38(10): 973-973.
[2]	许芳, 宋博文, 李璐瑶. 基于中医心身整体观的老年慢性病与心理健康关系研究[J]. 实用老年医学, 2024, 38(10): 990-992.
[3]	寇夕, 刘永宏, 董玮, 王华, 王宝梅, 高玉芳. 住院老年病人衰弱综合征与胰岛素样生长因子-1的相关性研究[J]. 实用老年医学, 2024, 38(5): 474-437.
[4]	庄鑫, 宗智颖, 徐花, 郑娟, 吴金芳, 刘恺航, 赵静, 张丽霞. 前馈控制训练对老年人跌倒风险的影响[J]. 实用老年医学, 2024, 38(5): 478-437.
[5]	杨琳琳, 张土明, 蔡钰莹, 罗金花, 杨宇. 社会支持与老年衰弱的研究进展[J]. 实用老年医学, 2024, 38(5): 525-437.
[6]	李婕, 王潇, 俞静, 刘娟, 陈姝, 佟蔷薇. 不同静息能量消耗预测方程在老年衰弱病人中的准确性比较[J]. 实用老年医学, 2024, 38(3): 293-295.
[7]	田甜, 张飞, 李铭麟, 张璇, 王佳贺. 人工智能助力改善老年听力障碍的研究进展[J]. 实用老年医学, 2024, 38(2): 114-118.
[8]	王佳贺. 前言——常见老年综合征与抑郁症的关系[J]. 实用老年医学, 2023, 37(3): 217-218.
[9]	穆白雪, 李铭麟, 张成普. 老年营养不良与抑郁症的研究进展[J]. 实用老年医学, 2023, 37(3): 219-222.
[10]	权紫微, 李铭麟, 苑莉莉, 王佳贺. 老年慢性疼痛与抑郁症的关系研究进展[J]. 实用老年医学, 2023, 37(3): 223-225.
[11]	刘继业, 孟红. 肌少症与抑郁症关系的研究进展[J]. 实用老年医学, 2023, 37(3): 230-233.
[12]	邹函怡, 王艺桦, 高明, 李关东, 高理升, 马祖长. 社区老年人肌少症患病现状及影响因素分析[J]. 实用老年医学, 2023, 37(3): 246-250.
[13]	史晓兰, 欧阳晓俊, 沈玲玉, 沈晓星. 老年住院病人内在能力下降与衰弱的相关性分析[J]. 实用老年医学, 2023, 37(3): 256-260.
[14]	杨梦娇, 詹云亮, 高梅. 肌少症病人的麻醉前评估[J]. 实用老年医学, 2023, 37(3): 304-307.
[15]	夏晶颖, 张倩. 老年营养风险指数联合降钙素原清除率和中性粒细胞/淋巴细胞比值对老年脓毒症病人短期预后的预测价值[J]. 实用老年医学, 2023, 37(2): 134-137.